Robert W. Baird analyst Catherine Ramsey Schulte maintained a Buy rating on NanoString Tech (NASDAQ:NSTG) on Wednesday, setting a price target of $71, which is approximately 16.66% above the present share price of $60.86.
Ramsey Schulte expects NanoString Tech to post earnings per share (EPS) of -$0.62 for the third quarter of 2021.
The current consensus among 3 TipRanks analysts is for a Moderate Buy rating of shares in NanoString Tech, with an average price target of $73.67.
The analysts price targets range from a high of $85 to a low of $65.
In its latest earnings report, released on 03/31/2021, the company reported a quarterly revenue of $31.62 million and a net profit of -$25.87 million. The company's market cap is $2.75 billion.
According to TipRanks.com, Robert W. Baird analyst Catherine Ramsey Schulte is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 36.8% and a 79.71% success rate.
NanoString Technologies, Inc. engages in the provision of life science tools for translational research and molecular diagnostic products. It offers analysis solutions, gene expression panels, protein assays, DNA Assaya, miRNA assays, vantage 3D assays, custom solutions, sample prep and nCounter consumables, and nDesign gateway. The company was founded by Amber Ratcliffe, Krassen Dimitrov, and Dwayne Dunaway on June 20, 2003 and is headquartered in Seattle, WA.